Harfang Receives Notice From Li-FT Power of Advancement To Second Option at Pontax, Quebec

Harfang Receives Notice From Li-FT Power of Advancement To Second Option at Pontax, Quebec GlobeNewswire September 23, 2025 MONTREAL, Sept. 23, 2025 (GLOBE NEWSWIRE) — Harfang Exploration Inc. (TSX.V: HAR) (“Harfang” or the “Company“) announced today that it has received notice from Li-FT Power Ltd. (“LIFT“) (TSX.V: LIFT) of its decision to proceed with the […]

Lost Money on Charter Communications, Inc. (CHTR)? Join Class Action Before October 14, 2025 – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / September 23, 2025 / If you suffered a loss on your Charter Communications, Inc. (NASDAQ:CHTR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/charter-communications-inc-lawsuit-submission-form?prid=169050&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Powell Max Limited Announces First Half 2025 Unaudited Financial Results

(NASDAQ:PMAX), HONG KONG, Sept. 23, 2025 (GLOBE NEWSWIRE) — Powell Max Limited (Nasdaq: PMAX) (the “Company” or “Powell Max“), a financial communications services provider headquartered in Hong Kong, today announced its unaudited interim condensed financial results for the six months ended June 30, 2025. Overview: Revenue was HK$23.9 million (US$3.1 million) for the six months

Powell Max Limited Announces First Half 2025 Unaudited Financial Results

Powell Max Limited Announces First Half 2025 Unaudited Financial Results GlobeNewswire September 23, 2025 HONG KONG, Sept. 23, 2025 (GLOBE NEWSWIRE) — Powell Max Limited (Nasdaq: PMAX) (the “Company” or “Powell Max“), a financial communications services provider headquartered in Hong Kong, today announced its unaudited interim condensed financial results for the six months ended June

Moxies Enters D.C. Dining Scene with Flagship Debut in the Nation’s Capital

WASHINGTON, Sept. 23, 2025 (GLOBE NEWSWIRE) — Celebrated for its fresh, globally inspired cuisine, signature cocktails and elevated hospitality, Moxies will open its first Washington, D.C. location at the end of this year and ninth location in the US. Situated at 1111 20th Street NW, just south of Dupont Circle, the new flagship restaurant will

Moxies Enters D.C. Dining Scene with Flagship Debut in the Nation’s Capital

Moxies Enters D.C. Dining Scene with Flagship Debut in the Nation's Capital Former Director of Culinary and Executive Chef-turned-franchisee Brandon Thordarson to lead the brand's launch in landmark Dupont Circle opening GlobeNewswire September 23, 2025 WASHINGTON, Sept. 23, 2025 (GLOBE NEWSWIRE) — Celebrated for its fresh, globally inspired cuisine, signature cocktails and elevated hospitality, Moxies

Nepra Foods Inc. Announces Exclusive North American Distribution Agreement for Award-Winning Naki Manuka Honey

VANCOUVER, BC / ACCESS Newswire / September 23, 2025 / Nepra Foods Inc. (CSE:NPRA)(OTCQB:NPRFF)(FSE:2P6) ("Nepra" or the "Company"), a pioneer in specialty and allergen-free food innovations driving healthier futures, announces an exclusive agreement between Nepra Foods Ltd. and Naki New Zealand, a premier family-owned producer of Unique Manuka Factor (UMF) certified Manuka honey. This strategic

Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis

Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated in early 2028 Part A results demonstrated efficacy and safety; ATSN-201 on track to be first gene therapy and one-time treatment for XLRS DURHAM, N.C., Sept. 23, 2025 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage

Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis

Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis GlobeNewswire September 23, 2025 Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated in early 2028 Part A results demonstrated efficacy and

Scroll to Top